The Rosiglitazone Evaluated for CV Outcomes in Oral Agent Combination Therapy for Type 2 Diabetes (RECORD) study was the only prospective trial to directly assess CV outcomes in patients treated with rosiglitazone in addition to metformin or sulphonylureas ( Effects on Platelets Preclinical Studies In animal experiments, Sprague-Dawley rats treated with pioglitazone for 710 days showed delayed arterial thrombus formation by reduced ADP- and arachidonic acid-induced platelet aggregation ( in vitro ( Clinical Studies In clinical studies, pioglitazone administered for 3 weeks in obese women showed a significant reduction in platelet activation assessed by urinary TXB metabolite excretion (Sidhu et al., 2003), procoagulant mediators released by activated platelets
Pierre, talked me into doing a 5k run with her in May
Serial dilutions of lysates were plated on blood agar to quantify the number of intracellular bacteria
Hanks buffered saline solution (HBSS): 185 mg/L CaCl 2 2H 2 O
Preclinical studies have shown promising results, with GLP-1 agonists demonstrating the ability to protect cartilage and reduce inflammation in animal models of osteoarthritis
As the body gets older, glutathione levels typically decrease
